原发性胆汁性胆管炎治疗现状

doi:10.3969/j.issn.1672-5069.2021.03.038

摘要/Abstract

摘要： 原发性胆汁性胆管炎(PBC)是一种发生在肝内小胆管的慢性、进行性、非化脓性炎症。熊去氧胆酸是目前唯一的一线治疗药物,对奥贝胆酸、贝特类和免疫抑制剂等二线药物的疗效研究已经取得新进展,而非药物治疗措施的效果和安全性还在进一步探索中。对于PBC患者,不同的肝外表现也有不同的治疗方案。本文就PBC的治疗现状进行了综述,为临床治疗和研究提供思路。

关键词: 原发性胆汁性胆管炎, 熊去氧胆酸, 奥贝胆酸, 治疗

Abstract: Primary biliary cholangitis (PBC) is a chronic, progressive, non-suppurative inflammation of the small bile ducts in the liver. Ursodeoxycholic acid is the only first-line therapeutic drug at present. New progress has been made in the research on the efficacy of second-line drugs such as obieticholic acid, betts and immunosuppressants. The efficacy and safety of non-drug intervened measure are under investigation. There are also different treatment ways for different extrahepatic manifestations of patients with PBC. In this review, we put focus on the current progress of treatment for PBC patients.

Key words: Primary biliary cholangitis, Ursodeoxycholic acid, Obieticholic acid, Therapy

张鑫赫, 田昊宇, 李异玲. 原发性胆汁性胆管炎治疗现状[J]. 实用肝脏病杂志, 2021, 24(3): 453-456.

Zhang Xinhe, Tian Haoyu, Li Yiling. Current therapeutic strategy for patients with primary biliary cholangitis[J]. Journal of Practical Hepatology, 2021, 24(3): 453-456.

参考文献

[1] Wasik U, Kempinska-Podhorodecka A, Bogdanos H, et al. Enhanced expression of miR-21 and miR-150 is a feature of anti-mitochondrial antibody-negative primary biliary cholangitis. Mol Med,2020,26(1):8.
[2]王立峰,李元元,金磊,等.原发性胆汁性肝硬化的流行病学与自然史变迁.临床肝胆病杂志,2015,31(2):165-170.
[3] Ye HL, Zhang JW, Chen XZ, et al. Ursodeoxycholic acid alleviates experimental liver fibrosis involving inhibition of autophagy. Life Sci,2020,242:117175.
[4] Carbone M, Mells GF, Pells G, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid.Gastroenterology,2013,144(3):560-569.
[5] Hirschfield GM, Dyson JK, Alexander GJM, et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.Gut,2018,67(9):1568-1594.
[6] Fujita K, Nomura T, MorishitaA, et al. Prediction of transplant-free survival through albumin-bilirubin score in primary biliary cholangitis. J Clin Med,2019,8(8):1258.
[7] Huang C, Han W, Wang C, et al. Earlyprognostic utility of Gp210 antibody-positive rate in primary biliary cholangitis: A Meta-analysis. Dis Mark,2019,2019:9121207.
[8] Yoo JJ, Cho EJ, Lee B, et al. Prognosticvalue of biochemical response modeis for primary biliary cholangitis and the additional role of the neutrophil-to-lymphocyte ratio. Gut Liver,2018,12(6):714-721.
[9] Liberopoulos EN, Florentin M, Elisaf MS, et al. Fenofibrate in primary biliary cirrhosis: A pilot study. Open Cardiovasc Med J,2010,4:120-6.
[10] Cheung AC, Lapointe-Shaw L, Kowgier M, et al. Combined ursodeoxy cholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. Aliment Pharmacol Ther,2016,43(2):283-293.
[11] Dohmen K, Mizuta T, Nakamuta M, et al. Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol,2004,10(6):894-8.
[12] Levy C, Peter JA, Nelson DR, et al. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther,2011,33(2):235-242.
[13] Han XF, Wang QX, Liu Y, et al. Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy.J Dig Dis,2012,13(4):219-24.
[14] Grigorian AY, Mardini HE, Corpechot, et al. Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis.Clin Res Hepatol Gastroenterol,2015,39(3):296-306.
[15] Zhang Y, Li S, He L, et al. Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis.Drug Des Devel Ther,2015,9:2757-66.
[16] Klose G, Nitschmann S. Bezafibrate for primary biliary cholangitis: Bezafibrate in combination with ursodeoxycholic acid in primary biliary cholangitis (BEZURSO) trial.Internist (BERL),2018,59(12):1344-1346.
[17] Corpechot C, Chazouilleres O, Rousseau A, et al. Aplacebo-controlled trial of bezafibrate in primary biliary cholangitis.N Engl J Med,2018,378(23):2171-2181.
[18] Yin Q, Li J, Xia Y, et al. Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis.Drug Des Devel Ther,2015,9:5947.
[19] 奉白蕾,俞慧宏,沈薇.熊去氧胆酸联合苯扎贝特治疗难治性原发性胆汁性胆管炎的Meta分析.中国肝脏病杂志,2019,27(4):304-311.
[20] Dohmen K, Tanaka H, Haruno M. Effectiveness of fenofibrate in comparison to bezafibrate for patients withasymptomatic primary biliary cirrhosis.Fukuoka Igaku Zasshi,2013,104(10):350-361.
[21] Duan W, Ou X, Wang X, et al. Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA. Rev Esp Enferm Dig,2018,110(9):557-563.
[22] Yin Q, Li J, Xia Y, et al. Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis.Drug Des Devel Ther,2015,9:5407-5419.
[23] Zhang H, Yang J, Zhu R, et al. Combination therapy of ursodeoxycholic acid and budesonide for PBC-AIH overlap syndrome: a meta-analysis.Drug Des Devel Ther,2015,9:567-574.
[24] Floreani A, Sun Y, Zou ZS, et al. Proposed therapies in primary biliary cholangitis.Expert Rev Gastroenterol Hepatol,2016,10(3):371-382.
[25] Leuschner M, Maler KP, Schlichting J, et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial.Gastroenterology,1999,117(4):918-925.
[26] Angulo P, Jorgensen RA, Keach J, et al. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.Hepatology,2000,31(2):318-323.
[27] Pagan B, Erdozain JC, Comas C, et al. Budesonide combined with ursodeoxycholic acid in primary biliary cirrhosis with advanced liver damage.Eur J Intern Med,2006,17(7):508-510.
[28] Hempfling W, Grunhage F, Diger K, et al. Pharmacokinetics and pharmacodynamic action of budesonide in early-and late-stage primary biliary cirrhosis.Hepatology,2003,38(1):196-202.
[29] Rautiainen H, Karkkainen P, Karvonen AL, et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: A three-year randomized trial.Hepatology,2005,41(4):747-752.
[30] Rautiainen H, Farkkila M, Neuvonen M, et al. Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis.Aliment Pharmacol Ther,2006,24(11-12):1545-1552.
[31] Floreani A, Mangini C. Primary biliary cholangitis: Old and novel therapy. Eur J Intern Med,2018,47:1-5.
[32] Levy C. Evolving role of obeticholic acid in primary biliary cholangitis. Hepatology,2018,67(5):1666-1668.
[33] Bowlus CL. Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection. Hepat Med,2016,8:89-95.
[34] Hischfield GM, Mason A, Luketic V, etal. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.Gastroenterology,2015,148(4):751-761.
[35] Nevens F, Andreone P, Mazzella G, et al. Aplacebo-controlled trial of obeticholic acid in primary biliary cholangitis.N Engl J Med,2016,375(7):631-43.
[36] Bowlus CL, Pockros PJ, Kremer AE, et al. Long-term obeticholic acid therapy improves histological endpoints in patients with primary biliary cholangitis.Clin Gastroenterol Hepatol,2020,18(5):1170-1178.
[37] Ishigami F, Naka S, Takeshita K, et al. Bile salt tauroursodeoxycholic acid modulation of Bax translocation to mitochondria protects the liver from warm ischemia-reperfusion injury in the rat.Transplantation,2001,72(11):1803-7.
[38] Ma H, Zeng M, Han Y, et al. A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis.Medicine (Baltimore),2016,95(47):e5391.
[39] Paridaens A, Raevens S, Devisscher L, et al. Modulation of the unfolded protein response by tauroursodeoxycholic acid counteracts apoptotic cell death and fibrosis in a mouse model for secondary biliary liver fibrosis. Int J Mol Sci,2017,18(1):214.
[40] 陈佳良,杨雪,张群,等.熊去氧胆酸联合中药治疗对原发性胆汁性胆管炎患者生物化学应答的影响:一项基于真实世界的队列研究.中华肝脏病杂志,2018,26(12):909-915.
[41] Huang YQ. Recent advances in the diagnosis and treatment of primary biliary cholangitis.World J Hepatol,2016,8(33):1419-1441.
[42] Sargin G, Senturk T, Cildag S. Rituximab therapy in rheumatoid arthritis and primary biliary cholangitis.Reumatol Clin,2019,15(6):e166-e167.
[43] Khanna A, Jopson L, Howel D, et al. Rituximabis ineffective for treatment of fatigue in primary biliary cholangitis: A phase 2 randomized controlled trial.Hepatology,2019,70(5):1646-1657.
[44] Arsenijevic A, Harrell CR, Fellabaum C, et al. Mesenchymal stem cells as new therapeutic agents for the treatment of primary biliary cholangitis. Anal Cell Pathol(Amst),2017,2017:7492836.
[45] Fan J, Tang X, Wang Q, et al. Mesenchymal stem cells alleviate experimental autoimmune cholangitis through immunosuppression and cytoprotective function mediated by galectin-9.Stem Cell Res Ther,2018,9(1):237.
[46] Zhu Y, Wang Q, Tang X, et al. Mesenchymal stem cells enhance autophagy of human intrahepatic biliary epithelial cells in vitro.Cell Biochem Funct,2018,36(5):280-287.
[47] Lei J, Chai Y, Xiao J, et al. Antifibrotic potential of bone marrow-derived mesenchymal stem cells in biliary atresia mice.Mol Med Rep,2018,18(4):3983-3988.